BMP2K divergent transcript (BMP2K-DT)

BMP2K-DT refers to a noncoding RNA transcribed in the opposite direction to the coding BMP2K gene, most likely as a product of divergent transcription—a widespread genomic phenomenon where transcription initiates bidirectionally at gene promoters, producing noncoding, often unstable, RNAs in addition to a protein-coding transcript[3]. While such divergent noncoding RNAs (also called uaRNAs or PROMPTs) are pervasive, the majority lack characterized function, are not known to encode proteins, and are not established as molecular targets[3]. BMP2K-DT does not correspond to the well-characterized protein-coding gene BMP2K (bone morphogenetic protein 2-inducible kinase), which itself is a serine/threonine kinase with roles in cell differentiation and endocytosis[1][2][4]. There are no known drugs or disease implications directly associated with BMP2K-DT. The entity BMP2K-DT is not considered a target in the standard sense used in pharmacology or molecular medicine. If you intended to inquire about the canonical protein target BMP2K, refer instead to "bone morphogenetic protein 2-inducible kinase (BMP2K)". BMP2K-DT is likely a noncoding divergent transcript at the BMP2K locus, not a protein, receptor, or characterized target. If a functional or therapeutic relevance for BMP2K-DT is established by future research, this information does not currently appear in reliable sources[3]. Confusion may arise from conflating the protein-coding gene (BMP2K) with the divergent transcript (BMP2K-DT); they are distinct molecular entities.

Other names

BMP2K divergent transcriptBMP2K-DT